Investors
Investor Relations
TSXV:NRX | OTCQB:NRXBF | FSE: J90
Transforming Regenerative Medicine
Nurexone's mission is to pioneer regenerative medicine targeting nerve and tissue regeneration for recovery from Spinal Cord Injuries (SCI), Traumatic Brain Injury (TBI) and a wide variety of indications.
We're developing ExoPTEN, a first nanodrug aimed at motor, sensory and functional recovery form acute spinal cord injury
NRX stock price by TradingView
J90 stock price by TradingView
NRXBF stock price by TradingView
Get Investor Updates
Financials & Filings
2024
2023
Latest News
November 1, 2024
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
October 23, 2024
NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA
September 26, 2024
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
October 2, 2024
Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries
By Zacks Small Cap Research
Analyst Reports
Events
Sun | Mon | Tue | Wed | Thu | Fri | Sat |
---|---|---|---|---|---|---|
27
|
28
|
29
|
30
|
31
|
1
|
2
|
3
|
5
|
6
|
7
|
8
|
9
| |
10
|
11
|
13
|
14
|
15
|
16
| |
17
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|